Needham & Company Reiterates a 'Buy' on Mattson Technology (MTSN); With Profitability In Sight, the Stock Looks Undervalued
Get Alerts MTSN Hot Sheet
Price: $3.60 --0%
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 13
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 13
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Mattson Technology (NASDAQ: MTSN) price target raised from $3.00 to $3.50.
Analyst, Y. Edwin Mok, said, "Mattson reported strong 4Q11 results that surpassed guidance range, and provided higher 1Q12 outlook. Based on new customer penetration of its RTP and etch products in multiple foundries, we believe MTSN is well positioned to see continued growth in the next few quarters. Additionally, the company is finally serious about reducing costs. We believe several phases of cost cutting measures, coupled with top-line growth, will allow MTSN deliver profitability within this year."
For an analyst ratings summary and ratings history on Mattson Technology click here. For more ratings news on Mattson Technology click here.
Shares of Mattson Technology closed at $2.39 yesterday.
Analyst, Y. Edwin Mok, said, "Mattson reported strong 4Q11 results that surpassed guidance range, and provided higher 1Q12 outlook. Based on new customer penetration of its RTP and etch products in multiple foundries, we believe MTSN is well positioned to see continued growth in the next few quarters. Additionally, the company is finally serious about reducing costs. We believe several phases of cost cutting measures, coupled with top-line growth, will allow MTSN deliver profitability within this year."
For an analyst ratings summary and ratings history on Mattson Technology click here. For more ratings news on Mattson Technology click here.
Shares of Mattson Technology closed at $2.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) PT Raised to $100 at Needham
- William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share